Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)
November 26 2021 - 1:32PM
Edgar (US Regulatory)
0001758736
false
September 30, 2021
12/31
2021
Q3
0001758736
2021-01-01
2021-09-30
0001758736
2020-12-31
0001758736
2021-09-30
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
iso4217:CNY
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16 UNDER
THE SECURITIES EXCHANGE ACT OF 1934
For the month of September 2021
Commission File Number: 001-39167
Molecular Data Inc.
11/F, Building 15, 2177 Shenkun Road
Minhang District, Shanghai 201106
People’s Republic of China
(Address of principal executive offices)
Indicate by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F.
Form 20-F ☒ Form 40-F
☐
Indicate by check mark if the registrant is submitting the Form 6-K
in paper as permitted by Regulation S-T Rule 101(b)(1): ☐
Indicate by check mark if the registrant is submitting the Form 6-K
in paper as permitted by Regulation S-T Rule 101(b)(7): ☐
Explanatory Note
On November 26, 2021, Molecular Data Inc. submitted
herewith an interim balance sheet as of the end of its third quarter.
Financial Statements and Exhibits.
SIGNATURES
Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto
duly authorized.
|
Molecular Data Inc.
|
|
|
|
|
By :
|
/s/ Steven Foo
|
|
Name :
|
Steven Foo
|
|
Title :
|
Chief Executive Officer and
Chief Financial Officer
|
Date: November 26, 2021
Exhibit 99.1
CONSOLIDATED STATEMENTS OF BALANCE SHEET
(Amounts in thousands of RMB and US$,
except for number of shares and per share data)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
As of December 31,
2020
|
|
|
As of September 30, 2021
|
|
|
|
(RMB’000)
|
|
|
(RMB’000)
unaudited
|
|
|
(USD’000)
|
|
Assets
|
|
|
|
|
|
|
|
|
|
|
|
|
Current assets:
|
|
|
|
|
|
|
|
|
|
|
|
|
Cash and cash equivalents
|
|
|
11,311
|
|
|
|
66,339
|
|
|
|
10,296
|
|
Restricted cash
|
|
|
277
|
|
|
|
—
|
|
|
|
—
|
|
Accounts receivable, net
|
|
|
5,963
|
|
|
|
6,211
|
|
|
|
964
|
|
Short-term investments
|
|
|
336,038
|
|
|
|
336,038
|
|
|
|
52,152
|
|
Unbilled receivables
|
|
|
51,825
|
|
|
|
56,842
|
|
|
|
8,822
|
|
Notes receivable
|
|
|
24,761
|
|
|
|
22,539
|
|
|
|
3,498
|
|
Inventories, net
|
|
|
2,821
|
|
|
|
5,784
|
|
|
|
898
|
|
Amounts due from related parties
|
|
|
1,144
|
|
|
|
7,178
|
|
|
|
1,114
|
|
Prepayments and other current assets
|
|
|
229,046
|
|
|
|
229,999
|
|
|
|
35,696
|
|
Total current assets
|
|
|
663,186
|
|
|
|
730,930
|
|
|
|
113,440
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Non-current assets:
|
|
|
|
|
|
|
|
|
|
|
|
|
Long-term investment
|
|
|
353
|
|
|
|
3,753
|
|
|
|
582
|
|
Property and equipment, net
|
|
|
725
|
|
|
|
469
|
|
|
|
73
|
|
Intangible assets, net
|
|
|
536
|
|
|
|
372
|
|
|
|
58
|
|
Deferred assets & deferred tax assets
|
|
|
15,826
|
|
|
|
7,773
|
|
|
|
1,206
|
|
Right-of-use asset, net
|
|
|
4,195
|
|
|
|
2,796
|
|
|
|
434
|
|
Total non current assets
|
|
|
21,635
|
|
|
|
15,163
|
|
|
|
2,353
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total assets
|
|
|
684,821
|
|
|
|
746,093
|
|
|
|
115,793
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Liabilities and Shareholders’ Equity
|
|
|
|
|
|
|
|
|
|
|
|
|
Current liabilities:
|
|
|
|
|
|
|
|
|
|
|
|
|
Short-term borrowings
|
|
|
33,749
|
|
|
|
16,149
|
|
|
|
2,506
|
|
Accounts payable
|
|
|
315,729
|
|
|
|
313,196
|
|
|
|
48,607
|
|
Deferred revenue
|
|
|
81,636
|
|
|
|
66,429
|
|
|
|
10,310
|
|
Accrued expenses and other liabilities
|
|
|
132,674
|
|
|
|
106,506
|
|
|
|
16,532
|
|
Convertible notes
|
|
|
16,096
|
|
|
|
39,453
|
|
|
|
6,123
|
|
Amounts due to related parties
|
|
|
111,186
|
|
|
|
119,531
|
|
|
|
18,551
|
|
Operating lease liabilities-current
|
|
|
1,536
|
|
|
|
1,393
|
|
|
|
216
|
|
Total current liabilities
|
|
|
692,606
|
|
|
|
662,657
|
|
|
|
102,845
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Non-current liabilities:
|
|
|
|
|
|
|
|
|
|
|
|
|
Non-current portion of capital lease obligations
|
|
|
17,052
|
|
|
|
17,052
|
|
|
|
2,646
|
|
Non-current portion of lease liability
|
|
|
2,659
|
|
|
|
1,403
|
|
|
|
218
|
|
Contingency liability
|
|
|
341
|
|
|
|
341
|
|
|
|
53
|
|
Total non-current liabilities
|
|
|
20,052
|
|
|
|
18,796
|
|
|
|
2,917
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total liabilities
|
|
|
712,658
|
|
|
|
681,453
|
|
|
|
105,762
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Redeemable noncontrolling interests
|
|
|
42
|
|
|
|
—
|
|
|
|
—
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Shareholders’ equity/(deficit)
|
|
|
|
|
|
|
|
|
|
|
|
|
Ordinary shares
|
|
|
114
|
|
|
|
202
|
|
|
|
31
|
|
Additional paid-in capital
|
|
|
1,075,064
|
|
|
|
1,231,970
|
|
|
|
191,199
|
|
Accumulated other comprehensive loss
|
|
|
(21,192
|
)
|
|
|
(21,192
|
)
|
|
|
(3,289
|
)
|
Accumulated deficit
|
|
|
(1,081,914
|
)
|
|
|
(1,146,669
|
)
|
|
|
(177,961
|
)
|
Total shareholders’
|
|
|
(27,928
|
)
|
|
|
64,311
|
|
|
|
9,980
|
|
Non-controlling interest
|
|
|
49
|
|
|
|
329
|
|
|
|
51
|
|
TOTAL (DEFICIT)/EQUITY
|
|
|
(27,879
|
)
|
|
|
64,640
|
|
|
|
10,031
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total liabilities and shareholders’ (deficit)/ equity
|
|
|
684,821
|
|
|
|
746,093
|
|
|
|
115,793
|
|
Molecular Data (NASDAQ:MKD)
Historical Stock Chart
From Aug 2024 to Sep 2024
Molecular Data (NASDAQ:MKD)
Historical Stock Chart
From Sep 2023 to Sep 2024